Abstract Breast cancers can be classified into those that express the estrogen (ER) and progesterone (PR) receptors, those with ERBB2 (HER-2/Neu) amplification, and those without expression of ER, PR, or amplification of ERBB2 (referred to as triple-negative or basal-like breast cancer). In order to identify potential molecular targets in breast cancer, we performed a synthetic siRNA-mediated RNAi screen of the human tyrosine kinome. A primary RNAi screen conducted in the triple-negative/basal-like breast cancer cell line MDA-MB231 followed by secondary RNAi screens and further studies in this cell line and two additional triplenegative/basal-like breast cancer cell lines, BT20 and HCC1937, identified the G2/M checkpoint protein, WEE1, as a potential therapeutic target. Similar sensitivity to WEE1 inhibition was observed in cell lines from all subtypes of breast cancer. RNAi-mediated silencing or small compound inhibition of WEE1 in breast cancer cell lines resulted in an increase in cH2AX levels, arrest in the S-phase of the cell cycle, and a significant decrease in cell proliferation. WEE1-inhibited cells underwent apoptosis as demonstrated by positive Annexin V staining, increased sub-G1 DNA content, apoptotic morphology, caspase activation, and rescue by the pan-caspase inhibitor, Z-VAD-FMK. In contrast, the non-transformed mammary epithelial cell line, MCF10A, did not exhibit any of these downstream effects following WEE1 silencing or inhibition. These results identify WEE1 as a potential molecular target in breast cancer.
Introduction
Breast cancer is a heterogeneous group of diseases. Approximately 60-70% of breast cancers express estrogen receptors (ER) and/or progesterone receptors (PR), and approximately 20-30% of breast cancers have amplified ERBB2 (HER-2) thus expressing high levels of the HER-2 protein [1, 2] . In approximately 15-20% of patients with breast cancer, the tumors do not express ER or PR and do not have amplification of ERBB2 [1] . These are often categorized as triple-negative breast cancer, and patients with these tumors have a poor prognosis [1] . Molecular classification by expression profiling of primary breast cancers and breast cancer cell lines has determined that the majority of these triple-negative tumors share expression profiles with basal epithelial cells of the breast duct [3] [4] [5] [6] and hence are also referred to as basal-like tumors. Currently, the mainstay of treatment for these tumors is chemotherapy [1] . Thus, identification of novel, molecularly targeted therapies for triple-negative/basal-like breast cancer in particular or for breast cancer in general, would be of great benefit.
The tyrosine kinases (TKs) constitute a protein family of approximately 90 members that play an integral role in signal transduction of mammalian cells including critical cellular processes as diverse as proliferation, apoptosis, differentiation, and cell motility [7] . Thus, it is not surprising that deregulation of TKs activity has been observed in numerous types of malignancy [8] . A number of TKs have been validated as therapeutic targets in human malignancies including both receptor TKs (e.g., EGFR, ERBB2/HER-2/Neu, Kit, and VEGF receptors) and nonreceptor TKs (e.g., BCR-ABL) [9] . We took advantage of the description of the complete human kinome [7] to apply a systematic functional genomics approach to reduce specifically the expression of each of the TKs using RNA interference (RNAi) in breast cancer cell lines and to investigate the consequences of the kinase loss of function on cell growth. Genome-wide application of RNAi-based screening has been used previously to identify genes that regulate processes such as apoptosis and cell cycle progression [10] [11] [12] . Thus, this methodology is particularly well suited in evaluating the role that each TK plays in the growth and survival of breast cancer cells and has the potential to identify novel molecular targets for patients with breast cancer.
Using synthetic siRNA-mediated RNAi screens of the human tyrosine kinome, we have identified the G2/M checkpoint kinase WEE1 as a potential molecular target for breast cancer. Further, we show that inhibition of WEE1 results in the accumulation of DNA damage, alteration in cell cycle regulation, and induction of apoptosis in breast cancer cells.
Materials and methods

Cell culture
The MDA-MB231 (MB231), HCC38, HCC1954, MB453, MB468, MCF7, MCF10A, SKBR3, T47D, and ZR75 cell lines were obtained from ATCC (Manassas, VA); BT20 and HCC1937 were obtained from Reinhard Ebner (Avalon Pharmaceuticals, Germantown, MD); NIH/3T3 cells were a gift from Dr. Micheal Birrer, Harvard Medical School, Boston, MA. MB231 cells were grown in RPMI 1640 supplemented with 5% fetal bovine serum (FBS), (R5), NIH/3T3 cells were grown in DMEM supplemented with 10% FBS, MCF10A cells were grown in DMEM F12 supplemented with 5% horse serum, 1.4 lM cortisone, 10 lg/ml insulin, 100 ng/ml cholera toxin, and 20 ng/ml Epidermal Growth Factor and all other cells were grown in RPMI 1640 supplemented with 10% FBS (R10). All growth media contained 100 units/ml of penicillin and 100 units/ml of streptomycin.
Gene-specific RNAi analysis Gene-targeted silencing was performed as described in the Supplementary methods.
Lysate preparation and histone extraction
Cell lysates were made as described previously [13] . Protein concentration was determined by using the Bio-Rad colorimetric assay (Bio-Rad, Hercules, CA). To extract histones, the pellets obtained after clarification were solubilized in 0.2 N HCl overnight at 4°C, neutralized with 2.0 M NaOH, and the protein was measured [14] .
Immunoblotting Immunoblotting was performed as described earlier [13] , and the antibodies are listed in Supplementary Table 1 .
Inhibitors
WEE1 inhibitor II (6-Butyl-4-(2-chlorophenyl)-9-hydroxypyrrolo [3,4-c] carbazole-1,3-(2H,6H)-dione, 681641, Calbiochem, La Jolla, CA) and the pan-caspase inhibitor, Z-VAD-FMK (P416, Biomol International, Plymouth Meeting, PA) dissolved in DMSO, were used at 10 and 100 lM concentrations, respectively.
Trypan blue staining
Cells were incubated with Trypan blue stain (15250-061, Invitrogen, Carlsbad, CA) after transfection with siRNA or treatment with inhibitors. Cells that excluded the dye (viable) and cells that retained the dye (dead) were counted.
Annexin V staining
After treatment with WEE1 inhibitor or DMSO, cells were stained using Annexin V-FITC Apoptosis Detection kit II (51-6710AK, BD Pharmingen, San Diego, CA) as per the manufacturer's protocol and were analyzed on a BD FACSCalibur (BD Biosciences, San Diego, CA) using FLOWJO software.
Caspase-Glo 3/7 assay Cells were plated in 100 ll at a concentration of 3,000 cells/well, in replicates of 6 wells, in a black-walled 96-well plate and allowed to adhere overnight. Z-VAD-FMK or DMSO was added for 2 h, and cells were then treated with WEE1 inhibitor or DMSO for 4, 8, or 24 h at 37°C. The plate was brought to room temperature and 100 ll of the Caspase-Glo 3/7 reagent (G8091, Promega, Madison, WI) was added to each well. The plate was incubated at room temperature for 45 min in the dark and read using a luminescence plate reader (VICTOR X, PerkinElmer Waltham, MA). Results are shown as mean ± SE of three independent experiments normalized to DMSO-treated cells.
Immunofluorescence
Cells grown in chamber slides were treated with WEE1 inhibitor or DMSO (control) for 4 or 24 h, washed with PBS and fixed in 3.7% paraformaldehyde for 15 min at room temperature. Cells were washed three times with PBS for 10 min, permeabilized with 0.2% Triton X-100 in PBS/ 1% BSA on ice for 5 min, washed in PBS/1% BSA, blocked at room temperature (PBS/3% BSA) for 1 h and incubated with anti-phospho-histone H2AX antibody at room temperature (1:500 in PBS/1% BSA/0.5% Tween 20) for 1 h. After washing with PBS/1% BSA/0.5% Tween 20 (39, 10 min each), cells were incubated with secondary antibody (1:5,000 of anti-mouse Alexa-Fluor 488) in 3%BSA/PBS at room temperature for 1 h, washed (49, 10 min each), mounted using Vectashield containing DAPI (H1200, Vector Laboratories, Burlingame, CA), and visualized under a confocal microscope (LSM 510, Carl Zeiss Microimaging, Germany).
Cell cycle analysis
Cells (1 9 10 6 ) were plated overnight, treated with WEE1 inhibitor as indicated, incubated with 10 lM BrdU (5002, Sigma-Aldrich, St Louis, MO) for 15 min, trypsinized, washed with PBS, and fixed in cold 70% ethanol. Staining was performed with anti-BrdU-FITC antibody (347583, BD Biosciences) and 5 lg/ml propidium iodide (PI) (P3566, Invitrogen). Analysis was performed on the BD FACSCalibur using FLOWJO software.
Statistics
Statistical comparison of mean values was performed using the paired Student's t-tests. All P values are 2 tailed.
Results
Identification and validation of WEE1 as a target from the RNAi screen
To identify TKs that may be therapeutic targets for treatment of breast cancer, we performed an RNAi-based functional genomic screen of the human tyrosine kinome in cell lines representative of triple-negative/basal-like breast cancer (see supplementary methods, supplementary results and supplementary Figs. 1-3 ). This screen identified the G2/M checkpoint protein WEE1 as a potential target kinase. The viability of three triple-negative/basal-like breast cancer cell lines MB231, BT20, and HCC1937 was inhibited by more than 60% upon silencing of WEE1 (WEE1 siRNA pool) 5 days post-transfection compared to a non-targeting control siRNA pool (Fig. 1a) . Triplenegative/basal-like breast cancer cells are classified into two subtypes: Basal A (BaA) and Basal B (BaB) based on the hierarchical clustering of their transcriptional profiles [6] . The three cell lines used in these studies represented both BaA (BT20 and HCC1937) and BaB (MB231) subtypes of triple-negative/basal-like breast cancer. Importantly, silencing of WEE1 in the non-transformed basal-like breast epithelial cell line, MCF10A, had little or no effect on cell viability (Fig. 1a) . To further confirm that the specific inhibition of WEE1 by the siRNA pool was responsible for the reduction in the viability of MB231 cells, each siRNA of the pool was tested individually (Fig. 1b) . Of the four siRNAs, two: numbers 6 and 8, reduced WEE1 protein and cell viability to levels comparable to that seen following transfection of the pooled WEE1 siRNAs. MB231 cells transfected with the WEE1 siRNA pool and the individual WEE1 siRNAs numbers 6 and 8 also exhibited a decrease in the phosphorylation of CDC2 on tyrosine 15, the substrate for WEE1 [15] . By contrast, WEE1 siRNA number 7 had little effect on WEE1 protein levels or CDC2 tyrosine phosphorylation and did not significantly affect cell viability. Interestingly, WEE1 siRNA number 5 had an intermediate effect on WEE1 protein levels and CDC2 tyrosine phosphorylation but no significant effect on cell viability. This suggests that there may be a threshold level above which WEE1 function is adequate to maintain cell viability.
Inhibition of WEE1 decreases the viability of breast cancer cell lines but not of non-transformed cells
Having identified WEE1 as a potential molecular target by the RNAi screen, we tested the effect of a specific inhibitor of WEE1 (WEE1 inhibitor II) on the survival of different breast cancer cells. WEE1 inhibitor II is a relatively specific small molecule inhibitor targeting the ATP-binding site of WEE1 [16] . Treatment of ER-positive breast cancer cell lines (MCF7, T47D, ZR75), HER2 amplified cell lines (MB453, SKBR3, HCC1954), and triple-negative/basallike breast cancer cell lines [HCC1937, BT20, MB468 (BaA) or HCC38, MB231 (BaB)] with the WEE1 inhibitor resulted in decreased cell growth similar to WEE1 silencing (Fig. 1c) . Importantly, the WEE1 inhibitor had no effect on the viability of the non-transformed MCF10A cells (Fig. 1c) or NIH3T3 fibroblasts (data not shown). Also, WEE1 inhibition led to a decrease in phosphorylation on Tyr15 of CDC2 (Fig. 1c) , consistent with our data obtained following transfection of WEE1 siRNAs (Fig. 1b) . This data suggests that the breast cancer cell lines of various subtypes (ER-positive, HER2 amplified and triple-negative/basal-like A or B) are sensitive to the downstream effects of WEE1 inhibition, and thus WEE1 could be a potential target in treatment of all subsets of breast cancer. Sensitivity to WEE1 loss has been linked previously to high levels of WEE1 expression [17] . However, we did not observe a difference in either expression or function of WEE1 that correlated with the sensitivity of the cancer cells to the loss of WEE1 function ( Supplementary Fig. 4 ). Sequence analysis of WEE1 mRNA did not reveal any evidence of activating mutations nor is there evidence of gene amplification of the WEE1 locus in the cancer cell lines (data not shown).
The MTS assay measures the metabolic activity of cells and as such is used as an estimate of cell viability. To more directly assess the effect of WEE1 loss of function on the number of viable and dead cells within a cell population, we stained the cells transfected with either WEE1 siRNA or control siRNA with Trypan blue. Silencing of WEE1 reduced the number of viable cells significantly in all three breast cancer cell lines tested (MB231, BT20, and HCC1937) but not in MCF10A cells (Fig. 2a) . There was also a corresponding increase in the percentage of dead cells in the breast cancer cell lines but not in MCF10A cells upon WEE1 silencing (Fig. 2b) . Also, the effect of WEE1 inhibition on non-transformed NIH/3T3 fibroblasts was examined (Supplementary Fig. 6a, b Fig. 6b ). Thus, this data indicate that the loss of WEE1 function induces death of breast cancer cell lines but not of non-transformed cell lines.
Inhibition of WEE1 in breast cancer cell lines induces apoptosis WEE1 inhibitor treated MB231 cells but not MCF10A cells exhibited membrane blebbing and fragmented nuclei consistent with apoptosis (Fig. 2c) . To further determine if apoptosis underlies the cell death seen following loss of WEE1 function, we measured DNA fragmentation by FACS analysis of PI stained cells following WEE1 inhibition. In MB231 cells, we observed a fourfold increase in cells with sub-G1 DNA content, whereas no increase was observed in MCF10A cells (Fig. 3a) . We also performed Annexin V staining of MB231 cells treated with the WEE1 inhibitor.
There was a significant increase in the percentage of Annexin V-positive cells upon WEE1 inhibition (Fig. 3b) . Also, fivefold increase in caspase-3/7 activity was observed upon WEE1 inhibitor treatment in MB231 cells that was blocked by the pan-caspase inhibitor, Z-VAD-FMK (Fig. 3c) .
Corresponding to the decrease in caspase activity, Z-VAD-FMK significantly reduced the percentage of dead cells as measured by Trypan blue staining (Fig. 3d) . Together, these results indicate that WEE1 inhibition results in caspasemediated apoptosis in breast cancer cells.
Inhibition of WEE1 causes S-phase arrest in breast cancer cell lines
As WEE1 is an important negative regulator of the G2/M checkpoint that controls mitotic entry of the cells [15] , we used PI and BrdU labeling to study the effects of WEE1 inhibition on the cell cycle profile of the breast cancer cells and non-transformed MCF10A cells (Fig. 4 , Supplementary Fig. 5 ). In MB231 cells, WEE1 inhibition at 24 h resulted in an increase in the fraction of cells arrested in S-phase and a concomitant decrease in the fraction of cells in the replicating S-phase ( Fig. 4a and Supplementary  Fig. 5a ). Also, there was an increase in the fraction of cells with sub-G1 DNA content (*tenfold) and a decrease in the fraction of cells in the G1-and the G2-phase of the cell cycle (Fig. 4a) . Similar results were observed in HCC1937 ( Supplementary Fig. 5b ). In contrast, WEE1 inhibition of the non-transformed MCF10A cells did not lead to S-phase arrest or increased cells with a sub-G1 DNA content ( Fig. 4b and Supplementary Fig. 5c ). In the MCF10A cells, a slight decrease in the G2-phase and the replicating S-phase cells and a slight increase in the G1-phase cells were seen, but these differences were not significantly different (Fig. 4b) . Similar to MCF10A, in NIH/3T3 cells there was no significant increase in the percentage of cells arrested in S-phase or in cells with sub-G1 DNA content upon WEE1 inhibition ( Supplementary Fig. 6c ).
Inhibition of WEE1 in cancer cell lines results in DNA damage
WEE1 is activated downstream of DNA damage sensed by the ATM and ATR kinases [18] . Thus, we looked for evidence of DNA damage in cells that had lost WEE1 function using phosphorylation of histone H2AX on Ser139 (cH2AX) as a marker of DNA double-strand breaks [19] . An increase in cH2AX levels was observed in the breast cancer cell lines, but not in the non-transformed MCF10A cells upon siRNA-mediated silencing of WEE1 or treatment with WEE1 inhibitor (Fig. 5a ). In addition, WEE1 inhibition did not increase cH2AX levels in the non-transformed NIH/3T3 cells ( Supplementary Fig. 6d ). Also, evident was an increase in cH2AX foci in MB231 cells (Fig. 5b ) after 4 h of treatment with the WEE1 inhibitor. In contrast, no increase in cH2AX foci was observed in MCF10A cells (Fig. 5b) . To check if DNA damage preceded cell cycle arrest and caspase activation, cH2AX levels, the percent of cells arrested in the S-phase, and caspase activation were measured in MB231 cells at different time points after WEE1 inhibition. An increase in cH2AX was evident as early as 4 h after the addition of the WEE1 inhibitor ( Fig. 5c upper panel) . WEE1 inhibition induced a moderate increase in the percentage of arrested S-phase cells by 8 h that increased by 24 h (Fig. 5c middle panel) . Interestingly, caspase activation was observed only at 24 h (Fig. 5c lower panel) .
The caspase inhibitor Z-VAD-FMK blocks caspase activation and the death of MB231 cells following WEE1 inhibition (Fig. 3d) . However, Z-VAD-FMK did not prevent an increase in cH2AX levels following WEE1 inhibition (Fig. 6a) . In contrast, the induction of DNA damage (as measured by increased cH2AX) by TNF-related apoptosisinducing ligand (TRAIL) is reversed in the presence of Z-VAD-FMK (Fig. 6b) . This suggests that WEE1 inhibition causes DNA damage followed by caspase activation, whereas TRAIL triggers caspase activation that is upstream of DNA damage. Similarly, the fraction of cells undergoing S-phase arrest upon WEE1 inhibition was not significantly affected by caspase inhibition (Fig. 6c) . Thus, at least in the context of breast cancer cells, WEE1 inhibition results in DNA damage, followed by S-phase arrest, caspase activation, and caspase-mediated apoptotic cell death.
Discussion
We performed a functional genomic screen of the tyrosine kinome to identify potential molecular targets in breast cancer cells and identified WEE1 as a promising target. TKs play an important role in cancer development and progression, and mutated TKs aid in the progression of human malignancies and cancer [8] . RNAi-mediated silencing of TKs has identified several potential molecular targets in cancer [12, 20] . To identify TK targets for the potential treatment of breast cancer, we used a systematic approach beginning with a primary screen of all 89 TKs in one representative triple-negative/basal-like (BaB) breast cancer cell line, MB231. Secondary screens and corroboration of the phenotypic effects of RNAi-mediated loss of function using independent siRNAs in other triplenegative/basal-like breast cancer cell lines followed. Of the 89 TKs targeted in the primary screen, the silencing of most of them reduced the viability of MB231 cell to some degree ( Supplementary Fig. 1 ). This is not surprising as TKs play essential roles in regulating many fundamental processes such as growth and apoptosis [10, 11] . Several kinases were initially identified through our screening efforts as potential targets. However, a reduction in cell viability was not observed with an independent pool of siRNAs corresponding to these TKs. This phenotypic disparity could be a result of the difference in the degree of silencing mediated against each target TK gene by the two different pools and/or the differences in the combination of on-and off-target effects of each gene-specific siRNA pool. However, for WEE1, we saw consistency between the phenotypic effects mediated by both the pools of siRNAs targeting this TK and individual WEE1 siRNAs. Our follow-up screens and experimentation led us to focus on the G2/M checkpoint protein WEE1 ( Supplementary Figs. 2-3 ). WEE1 is a key element in the DNA damage response pathway. Upon DNA damage, the cellular sensors ATM and ATR are activated, leading to phosphorylation of the checkpoint kinases CHK1 and CHK2. CHK1 in turn phosphorylates WEE1 and activates it [21] . Activated WEE1 causes an inhibitory phosphorylation of CDC2/ CDK1 on Tyr15, which then prevents cells from entering mitosis allowing time for DNA repair prior to entering mitosis [15] . In our experiments, loss or inhibition of WEE1 in eleven breast cancer cell lines, representing ERpositive, HER2 amplified, and triple-negative/basal-like subtypes of breast cancer, resulted in cell death (Fig. 1) . A recent functional genomic screen of several cancer cell lines identified WEE1 as a potential molecular target in HeLa cells and Cal51, a triple-negative breast cancer cell line with luminal features [17, 22] . Reports from several groups have suggested that inhibition of WEE1 can enhance the effects of radiation-or chemotherapy-induced DNA damage in colon cancer cells, lung cancer cells, and melanoma cells [23] [24] [25] [26] . Thus, WEE1 may be a molecular target in a broad range of cancers, including breast cancers. Loss or inhibition of WEE1 in breast cancer cell lines resulted in DNA damage, S-phase arrest, and the induction of caspase-mediated apoptosis (Figs. 2, 3, 4, 5 and 6 ). The mechanism that accounts for the caspase activation and subsequent cell death is not clear; although, the time course experiments demonstrate that the appearance of DNA damage (at 4 h) preceded cell cycle arrest (seen at 8 h) and caspase activation (seen at 24 h) (Fig. 5c) . Caspase inhibition prevented cell death but not the accumulation of DNA damage or cell cycle arrest (Figs. 3, 6 ). This is consistent with a model whereby DNA damage results in S-phase arrest, which in turn activates caspases. Alternatively, the DNA damage itself may directly induce both caspase activation and cell cycle arrest. Interestingly, loss or inhibition of the upstream checkpoint kinases, CHK1 or CHK2, have been found to cause DNA damage, cell cycle arrest, and cell death in cancer cells [27, 28] . A recent publication describes that the loss of CHK1 triggers caspase-2 mediated apoptosis in TP53-deficient cells [29] . Breast cancers are documented to have mutations or deletions of TP53 [6, 30] . Of the cell lines we tested for sensitivity to WEE1 inhibition, MB231, T47D, HCC38, MB468, SKBR3, HCC1954, HCC1937 contain either a mutant copy of TP53 or are null for TP53. MCF7, MB453, BT20, and ZR75 have wild-type TP53 [6, 31] . Interestingly, the caspase-2 inhibitor Z-VDVAD-FMK blocked caspase-3/7 activation and cell death following WEE1 inhibition in MB231 cells similar to the inhibition by the pan-caspase inhibitor Z-VAD-FMK (data not shown). However, siRNA-mediated silencing of caspase-2 did not protect these cells from apoptosis induced by WEE1 inhibition (unpublished observation). Thus, it is possible that the degree of silencing of caspase-2 was insufficient to prevent apoptosis. However, while Z-VDVAD-FMK has been described as a caspase-2-specific inhibitor, recent work suggests that it may inhibit multiple caspases similar to Z-VAD-FMK [32] [33] [34] . Further investigation will be required to identify the mechanism by which caspase activation is triggered upon the loss or inhibition of WEE1. This study and published data suggest that WEE1 inhibition has selective toxicity to cancer cells compared to normal cells [26] . In fact, WEE1 inhibitors are in phase I clinical trials in patients with cancer [35] . The basis for the selective toxicity of WEE1 loss or inhibition in breast cancer cell lines compared to non-transformed cells is not completely clear. In the functional genomic screen that identified WEE1 as a target in the Cal51 breast cancer cells, the authors found a relationship between high levels of WEE1 expression and sensitivity to WEE1 inhibition [17] . However, we found that the non-transformed breast basal epithelial cell line MCF10A is insensitive to WEE1 inhibition while expressing similar levels of WEE1 and had similar levels of WEE1 activity (measured by the levels of phosphorylated CDC2) as the cancer cells ( Supplementary  Fig. 4 levels. H2AX is shown as a loading control. c The percentage of cells arrested in S-phase for MB231 cells treated as in a for 24 h, was determined as described in Fig. 4 accumulation of DNA double-strand breaks as measured by the accumulation of cH2AX (Fig. 5 , Supplementary  Fig. 6d ). Phosphorylation of H2AX (cH2AX) is triggered by DNA double-strand breaks and mediates the formation of clusters of proteins called DNA damage response foci at the site of damage [19, 36] . One possible explanation for the selectivity of WEE1 inhibition for cancer cells is that the cancer cells have a pre-existing defect in DNA repair pathways and/or ongoing DNA damage. It has been postulated that many breast cancers are deficient in the homologous DNA repair pathway [30] . Thus, the loss of the G2/M checkpoint that results from the loss or inhibition of WEE1 may allow DNA damage to accumulate that would otherwise be repaired at this checkpoint. We saw no evidence of DNA damage in the non-transformed MCF10A cell line upon the loss of WEE1 function suggesting that the cancer cells are more prone to DNA double-strand breaks (Fig. 5 ). In addition, it appears that the cancer cells have more cH2AX foci than the non-transformed MCF10A cells prior to the inhibition of WEE1 function (Fig. 5b) . Consistent with this observation, recent studies have shown that untreated cancer cells have a relatively high number of cH2AX foci indicative of ongoing DNA double-strand breaks compared to normal cells [37] . Thus, the loss of the G2/M checkpoint may be particularly deleterious to cancer cells. Another striking difference we observed was the arrest of the cancer cells in S-phase upon the loss or inhibition of WEE1, while the non-transformed cells showed a slight increase in G1 but no S-phase arrest (Fig. 4 , Supplementary Figs. 5 and 6c). Eukaryotic cells have multiple checkpoints in the cell cycle that allow the faithful replication and transmission of DNA to daughter cells upon cell division [18] . Breast cancer cells have been shown to lack an active G1 checkpoint [30] . Interestingly, embryonic stem (ES) cells lack a functional G1 check point, and DNA damage induces S-phase arrest and apoptosis in them [38] . Restoration of the G1 check point in ES cells prevents radiation-induced apoptosis [38] . Our data are consistent with these observations, as the cancer cells, in the absence of a functional G1 checkpoint, arrest in S-phase when WEE1 function is lost. Consistent with the idea that transformed cells lose the G1 check point, a transformed variant of MCF10A cells exhibited increased cH2Ax levels, an increased percentage of cells arrested in S-phase, and an increased percentage of dead cells when treated with the WEE1 inhibitor (unpublished data). Whether it is the lack of DNA damage or the ability to repair DNA at the intact G1 checkpoint that allows the non-transformed cells to survive the loss of the G2/M checkpoint will require further study.
Our work suggests that WEE1 may be a useful target in breast cancer, including triple-negative/basal-like breast cancer. WEE1 inhibitors are currently undergoing clinical testing in phase I studies [35] . Recent work suggesting that triple-negative/basal-like breast cancers are defective in double-stranded DNA repair has led to clinical trials combining DNA-damaging agents such as platinum compounds with DNA repair inhibitors such as PARP inhibitors [39] [40] [41] . Interestingly, WEE1 serves as a critical component of the response to double-stranded DNA breaks by activating the G2/M checkpoint and allowing the cell to repair damaged DNA [18] . This suggests that the combination of DNA-damaging agents with WEE1 inhibition may be particularly effective in the triple-negative/basallike breast cancer cells. Reports from several groups have suggested that inhibition of WEE1 can enhance the effects of radiation-or chemotherapy-induced DNA damage in colon cancer cells, lung cancer cells, and melanoma cells [23] [24] [25] [26] . Our data, together with these observations, suggest that further study of WEE1 inhibition alone and particularly in combination with DNA-damaging agents in breast cancers is warranted.
